Abstract
In late 2019, coronavirus-2 (SARS-COV 2) infection emerged in Wuhan, China and spread to all countries making the first pandemic of the 21st century. It seems that this infection will persist which is long enough to obligate modifications in both lifestyle and health care systems. Because chronic liver diseases (CLD) are prevalent all over the world, it is expected to manage patients with CLD and COVID-19. The aim of this review was to shed light on the impact of COVID-19 pandemic on the management of patients with CLD and how to give medical care to CLD patients during COVID-19 pandemic.
Keywords: Coronavirus disease, COVID-19, pandemic, chronic liver diseases, cirrhosis, HCC.
Infectious Disorders - Drug Targets
Title:Modifications of Medical Care of Chronic Liver Diseases During COVID-19 Pandemic: Necessity or Novelty?
Volume: 21 Issue: 8
Author(s): Hanan Hamed Soliman, Mohamed H. Emara, Mahmoud Elkadeem and Sherief Abd-Elsalam*
Affiliation:
- Tropical Medicine and Infectious Diseases Department, Faculty of Medicine, Tanta University,Egypt
Keywords: Coronavirus disease, COVID-19, pandemic, chronic liver diseases, cirrhosis, HCC.
Abstract: In late 2019, coronavirus-2 (SARS-COV 2) infection emerged in Wuhan, China and spread to all countries making the first pandemic of the 21st century. It seems that this infection will persist which is long enough to obligate modifications in both lifestyle and health care systems. Because chronic liver diseases (CLD) are prevalent all over the world, it is expected to manage patients with CLD and COVID-19. The aim of this review was to shed light on the impact of COVID-19 pandemic on the management of patients with CLD and how to give medical care to CLD patients during COVID-19 pandemic.
Export Options
About this article
Cite this article as:
Soliman Hamed Hanan , Emara H. Mohamed , Elkadeem Mahmoud and Abd-Elsalam Sherief*, Modifications of Medical Care of Chronic Liver Diseases During COVID-19 Pandemic: Necessity or Novelty?, Infectious Disorders - Drug Targets 2021; 21 (8) : e160921189886 . https://dx.doi.org/10.2174/1871526520666210104152256
DOI https://dx.doi.org/10.2174/1871526520666210104152256 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Possible Placental Factor for Preeclampsia: sFlt-1
Current Medicinal Chemistry Antidotes for Acute Cyanide Poisoning
Current Pharmaceutical Biotechnology Citicoline and Retinal Ganglion Cells: Effects on Morphology and Function
Current Neuropharmacology Nociceptin /Orphanin FQ Peptide (NOP) Receptor Modulators: An Update in Structure-Activity Relationships
Current Medicinal Chemistry Editorial from Editor-in-Chief: Amniotic Pulmonary Embolism and the Respiratory System: Management Trends and Future Options
Current Respiratory Medicine Reviews Potential Role of Hydrogen Sulfide in the Pathogenesis of Vascular Dysfunction in Septic Shock
Current Vascular Pharmacology Bombacaceae Between the Ethnomedical Uses and Pharmacological Evidences: A Review
The Natural Products Journal Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Infection and Hemodialysis Access: An Updated Review.
Infectious Disorders - Drug Targets Influence of a Novel Inhibitor (UM8190) of Prolylcarboxypeptidase (PRCP) on Appetite and Thrombosis
Current Medicinal Chemistry Healthy Properties of Garlic
Current Nutrition & Food Science PARADIGM - HF: The Rise of the Arnis
Reviews on Recent Clinical Trials Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Anti-Cancer Agents in Medicinal Chemistry The Future of Interventional Management of Hypertension: Threats and Opportunities
Current Vascular Pharmacology Endovascular vs. Open Repair of Abdominal Aortic Aneurysms and Renal Function
Current Vascular Pharmacology Purine Ionotropic (P2X) Receptors
Current Pharmaceutical Design Small Molecules in Treatment of Sepsis
Current Drug Targets Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design The Pharmacological Effects of Novokinin; a Designed Peptide Agonist of the Angiotensin AT<sab>2</sab> Receptor
Current Pharmaceutical Design IL-1 Cytokines in Cardiovascular Disease: Diagnostic, Prognostic and Therapeutic Implications
Cardiovascular & Hematological Agents in Medicinal Chemistry